FDA Cosmetic Ingredient Review: How the CIR Panel Evaluates Safety and What It Means for Your Products

The Cosmetic Ingredient Review (CIR) is an independent, industry-funded expert panel that systematically reviews and assesses the safety of ingredients used in cosmetic products. Established in 1976 under the sponsorship of the Personal Care Products Council (formerly the Cosmetic, Toiletry, and Fragrance Association), the CIR operates independently from the industry and from the FDA, although the FDA participates as a non-voting liaison. For foreign cosmetic brands building safety substantiation files under MoCRA, CIR assessments are one of the most authoritative and widely accepted sources of ingredient safety data. Understanding how CIR evaluations work, what they cover, and how to use them in your safety documentation can significantly streamline the compliance process.

How the CIR review process works

The CIR Expert Panel consists of dermatologists, toxicologists, pharmacologists, and other scientists who review published and unpublished safety data on cosmetic ingredients. The review process begins with the identification of an ingredient or ingredient group for assessment, followed by a comprehensive literature search and data compilation. The panel then evaluates the data across multiple endpoints — including acute and chronic toxicity, reproductive and developmental toxicity, genotoxicity, carcinogenicity, dermal irritation and sensitization, phototoxicity, and absorption/penetration — and issues a final report with one of several possible conclusions: safe as used, safe with qualifications (specifying conditions such as concentration limits or restrictions on use), insufficient data to determine safety, or unsafe.

CIR reports are published in the International Journal of Toxicology and are publicly available through the CIR's online database. Each report includes a detailed review of the available safety data, the panel's analysis and reasoning, and the final safety conclusion. As of 2026, the CIR has reviewed over 1,200 ingredients (covering more than 5,000 individual ingredient names), making it one of the most comprehensive ingredient safety databases in the world. The panel continuously re-reviews ingredients as new data becomes available, and outdated assessments are updated to reflect current science.

CIR findings and MoCRA safety substantiation

Under MoCRA, the responsible person for a cosmetic product must maintain adequate substantiation of safety for each product and each ingredient. 'Adequate substantiation' means tests, studies, or other evidence that is considered among experts qualified by scientific training to be sufficient to support a reasonable certainty that the product is safe. CIR assessments directly support this requirement — a CIR finding that an ingredient is 'safe as used' or 'safe with qualifications' provides authoritative expert evaluation that can serve as a key component of the ingredient's safety substantiation file. The FDA recognizes CIR assessments and has historically relied on CIR findings when evaluating cosmetic ingredient safety.

However, a CIR assessment alone may not constitute complete safety substantiation for a finished product. The CIR evaluates individual ingredients, not finished formulations — interactions between ingredients, the specific concentration used, the product type (leave-on vs. rinse-off), and the intended use population (adults vs. children, general vs. eye area) all affect the safety profile of the finished product. A CIR finding that an ingredient is safe at concentrations up to 5 percent does not substantiate the safety of a product that uses the ingredient at 10 percent, or a product that combines the ingredient with other actives that may have synergistic effects.

Ingredients not reviewed by CIR

Not all cosmetic ingredients have been reviewed by the CIR. Novel ingredients, ingredients used primarily in non-US markets, and ingredients that entered the market after the most recent CIR review cycle may lack a CIR assessment. For these ingredients, the responsible person must rely on other sources of safety data — including toxicological studies, published literature, GRAS or food additive safety evaluations (where the same substance is used in food), evaluations by international bodies such as the EU Scientific Committee on Consumer Safety (SCCS), and the manufacturer's own safety testing data. Foreign brands that use ingredients with no CIR assessment should be prepared to compile a more extensive safety substantiation file from these alternative sources.

How FDABridge supports ingredient safety compliance

FDABridge provides MoCRA facility registration and product listing services for foreign cosmetic brands, ensuring the foundational regulatory filings are in place. Our team can advise on the documentation requirements for safety substantiation and help you understand which of your ingredients have existing CIR assessments and which may require additional safety data. Visit fdabridge.com/cosmetics to see our cosmetics services or fdabridge.com/contact to discuss your MoCRA compliance needs.